Quantcast

Kiadis Pharma Initiates Collaboration for Personalized Immunotherapies Using ATIR[TM]with Technische Universität München within Munich Biotech Cluster

January 29, 2014

AMSTERDAM, January 29, 2014 /PRNewswire/ –

~ Prof. Dr. Angela Krackhardt from the Klinikum rechts der Isar of the Technische
Universitat Muenchen to lead the project ~

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments
for blood cancers, today announces that it has initiated a collaboration to identify and
characterize leukemia-specific T-cells in Kiadis Pharma’s lead product ATIR[TM], that
would be responsible for the Graft-versus-Leukemia effect of the T-cell immunotherapy
product. The collaboration will be run with Prof. Dr. Angela Krackhardt who leads the
group of Translational Immunotherapy at the Department of Hematology (Prof. Christian
Peschel) of the Klinikum rechts der Isar of the Technische Universitat Muenchen.

The project, which has now commenced, was accepted by the Munich Biotech Cluster m4
and receives grant financing from the Cluster for Prof. Krackhardt’s group. In the Munich
Biotech Cluster, biotechnology companies and academic groups work together under the
guiding concept of Personalised Medicine on about thirty research projects, in which new
drugs and technologies are developed.

ATIRTM is a T-cell based medicinal product that is currently in international
multi-centre Phase II clinical trials as an adjunctive treatment after a T-cell depleted
haploidentical stem cell transplantation for patients for whom a matching donor cannot be
found (in time). ATIRTM is manufactured from lymphocytes collected from the same donor
that provides the graft for the stem cell transplantation of the patient. ATIRTM is
therefore a truly personalized immunotherapy.

Manfred Ruediger, PhD, Chief Executive Officer of Kiadis Pharma, commented: “We are
delighted about our collaboration with the group of Prof. Krackhardt and being part of the
Munich m4 Cluster family. We are confident that this will expedite the identification of
those T-cells in our lead product candidate, ATIR(TM), that are responsible for the
Graft-versus-Leukemia effect of the product. The Cluster’s expertise in immunotherapies
and the translational work of the University Clinic provide the optimal basis for the
success of this collaboration.”

Prof. Angela Krackhardt stated: “We are pleased about the joint project with Kiadis
Pharma. ATIR(TM) provides us with the perfect platform to identify (new)
Graft-versus-Leukemia T-cells. The proficiency of Kiadis Pharma and our own well
established expertise will result in a unique synergy.”

About ATIR(TM)

ATIR(TM) is a T-cell based medicinal product enabling stem cell transplantations using
partially mismatched (haploidentical) family members as donors for patients suffering from
blood cancer who do not have a standard of care stem cell donor available. A hematopoietic
stem cell transplantation (HSCT) is the only potentially curative option for many patients
but a matching donor is available for only half of the patients in need. ATIR(TM) thus has
the potential to address this unmet need and to make a HSCT available for all patients
worldwide.

Those T-cells in a haploidentical graft which would cause Graft-versus-Host-Disease
(GvHD) are selectively eliminated using proprietary technology to produce ATIR(TM).
ATIR(TM) is administered as an adjunctive treatment after a T-cell depleted haploidentical
HSCT facilitating early immune reconstitution without causing life-threatening (acute)
GvHD.

In a Phase I/II study in which high-risk leukemia patients with very poor prognosis
were treated with escalating doses of ATIR(TM) after a haploidentical HSCT, long-term
safety, efficacy and proof of concept were confirmed in terms of absence of Grade III/IV
(life-threatening) acute GvHD, reduced rates of infection, reduced Transplant Related
Mortality and high Overall Survival. Positive follow-up results from this study
demonstrating 67% survival after five years and no Transplant Related Mortality in the
nine patients who received an efficacious dose of ATIR(TM) were recently reported.

An international multi-center Phase II study including patients with acute myeloid
leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome, to corroborate and
extend the safety and efficacy results from the Phase I/II study, is now ongoing with
topline data expected in the first half of 2014.

ATIR(TM) has been granted Orphan Drug Designation both in the EU and the USA.
Together, both regions represent a combined primary market potential of more than EUR 1
billion per year.

About Kiadis Pharma

Kiadis Pharma B.V. is a private, clinical stage biopharmaceutical company focused on
the development of innovative and potentially life-saving therapies for patients with late
stage blood cancers and related disorders, an area of significant unmet medical need.

Kiadis Pharma’s lead product is ATIR(TM), a cell based product designed to enable stem
cell transplantations from partially mismatched (haploidentical) family donors. Kiadis
Pharma is collaborating with internationally renowned centers in Europe and North America
for the successful development and manufacturing of ATIR(TM). Kiadis Pharma recently
obtained a GMP manufacturing license and GMP certificate for its Quality Control
laboratory

Kiadis Pharma is supported by a strong group of leading international investors
including LSP, Alta Partners, DFJ Esprit, Quest for Growth, MedSciences Capital and NOM.
Kiadis Pharma is based in Amsterdam, The Netherlands. Further information can be found at:

http://www.kiadis.com

        Company Contact:
        Manfred Ruediger, CEO
        Kiadis Pharma
        Entrada 231-234
        1096 EG Amsterdam
        The Netherlands
        Tel. +31 20 314 02 50
        communication@kiadis.com

        Media and Investor Contact:
        Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
        Consilium Strategic Communications
        Tel: +44 (0) 207 920 2354
        kiadis@consilium-comms.com

SOURCE Kiadis Pharma


Source: PR Newswire



comments powered by Disqus